Research team describes a single case of CAR-negative T-cell lymphoma after CAR T cell therapy The development of any type of second cancer following CAR T cell therapy is a rare occurrence, as found in an analysis of more than 400 patients treated at Penn Medicine, researchers from the Perelman School of Medicine at the
An experimental drug designed to block blood-clotting proteins may lower the risk of recurrent strokes, according to a dose-finding trial published in The Lancet Neurology. More than 795,000 people in the United States each year suffer a stroke, according to the American Heart Association, and nearly one in five will go on to experience another stroke. “When patients
Hearing restoration was observed within 30 days of a single administration of AK-OTOF in the initial AK-OTOF-101 study participant, the first to receive gene therapy in the United States for a genetic form of hearing loss AK-OTOF is a gene therapy being developed for the treatment of sensorineural hearing loss due to mutations in the otoferlin gene (OTOF)
Approximately one in three deaths in the U.S. is caused by cardiovascular disease, according to the U.S. Centers for Disease Control and Prevention. A robust body of evidence shows aerobic exercise can reduce risks, especially for people who are overweight or obese. But few studies have compared results with resistance exercise — also known as strength
Long Covid patients suffer from chronic symptoms such as fatigue or shortness of breath. As researchers at the University of Zurich and University Hospital Zurich have discovered, this is to some extent due to a part of our immune system called the complement system. The study identified a pattern in the blood proteins that will
Guillain-Barré syndrome is a rare disease in which the immune system attacks the peripheral nerves. Those affected suffer from muscle weakness and paralysis. A research team led by ETH Zurich has now elucidated the mechanism of this autoimmune reaction. Patients with Guillain-Barré syndrome (GBS) suffer from a rare and diverse disorder of the peripheral nervous
Improving CART19 function by targeting a membrane-proximal CD19 epitope with fast on- and off-rates. Early results for the Penn Medicine-developed AT101 presented at ASH Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response
In an article published in the Journal of Applied Physiology, researchers at the University of São Paulo show that damage to small blood vessels in the lungs caused by SARS-CoV-2 is the main factor underlying severe COVID-19. Blood clotting (thrombosis) in the capillary vessels of the lungs is one of the first consequences of severe COVID-19,
The U.S. Food and Drug Administration approved two milestone treatments, Casgevy and Lyfgenia, representing the first cell-based gene therapies for the treatment of sickle cell disease (SCD) in patients 12 years and older. Additionally, one of these therapies, Casgevy, is the first FDA-approved treatment to utilize a type of novel genome editing technology, signaling an
Charité study highlights limits of large language models in precision medicine Treating cancer is becoming increasingly complex, but also offers more and more possibilities. After all, the better a tumor’s biology and genetic features are understood, the more treatment approaches there are. To be able to offer patients personalized therapies tailored to their disease, laborious
